A Brooklyn care briefing
The answer changes with the exact medicine
It is fair to ask if an offer is real and allowed. Get the exact product name, then ask whether the US medicine agency approved it for the use being proposed.
Approved products and other offers
The approval details below were checked on September 26, 2026. This is the date of the check, not when a medicine was approved. [a]
Approved examples
FDA is the Food and Drug Administration, the federal medicine agency.
Those records list semaglutide (Ozempic, Wegovy), plus tirzepatide (Mounjaro, Zepbound). Each one has set uses on its label. [a]
- Ask for the product name and the reason for offering it to you.
- Ask to see the information for that specific medicine.
Other names you may be offered
As of September 26, 2026, BPC-157 had no US approval record with FDA. [a]
Compounding prepares a medicine to fit what a patient needs.
Neither cagrilintide nor retatrutide may be used for compounding under federal law, FDA says. That legal position was checked September 26, 2026. [b]
- Do not treat a study name or a treatment menu as an approval record.
- Ask the prescriber whether the exact product has FDA approval for the proposed use.
A prescription does not settle the approval question
The clinician’s order for medicine is called a prescription.
Federal law requires a valid prescription for a prescription medicine; we checked this requirement on September 26, 2026. [c]
A medicine made to order does not gain FDA approval when a clinician writes a prescription for it. [d]
- Ask which kind of medicine is proposed: a product with FDA approval, or a medicine prepared to order.
- If it would be made to order, read the compounding briefing for the questions to ask.